Marcelo Gareca, MD
Infectious Disease · Allentown, PANPI 1346221959
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Viiv Healthcare Company accounts for 63.7% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $72, 4.4 times the $17 reported in 2019.
Across 9 payments — averaging $22.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$127
- Insmed, Inc.$36
- Pfizer$36
Across 108 payments — averaging $9626.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$345K
- Karyopharm Therapeutics Inc.$283K
- Hoffmann-la Roche Limited$207K
- Pfizer$205K
- Merck$500
What the payments were for
- Food & beverage$199100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 6 | $127 |
| Insmed, Inc. | 2 | $36 |
| Pfizer | 1 | $36 |
How this compares
$199 in reported general payments places this provider in the 55th percentile of 457 infectious disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Linezolid | 14 | $1,418 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 14 | $800 |
| Doxycycline Hyclate | 14 | $739 |
| Cephalexin | 30 | $444 |
| Mupirocin | 14 | $67 |
| Ciprofloxacin Hcl | 16 | $65 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $37 |
| Single Use SwabAlcohol Antiseptic Pads | 13 | $23 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Allentown
- Margaret HoffmanterryAllentown$125K
- David HornPhiladelphia$2.1M
- Judith WolfPhiladelphia$1.2M
- Karam MounzerPhiladelphia$712K
- William ShortPhiladelphia$520K
- David WuWest Chester$483K
- William PaceSouthampton$472K
- Amesh AdaljaPittsburgh$415K
- Brett GilbertWynnewood$352K
- Timothy BabinchakPhoenixville$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.